DSpace DSpace UPC
 Català   Castellano   English  

E-prints UPC >
Altres >
Enviament des de DRAC >

Empreu aquest identificador per citar o enllaçar aquest ítem: http://hdl.handle.net/2117/6185

Ítem no disponible en accés obert per política de l'editorial

Arxiu Descripció MidaFormat
a single-center randomized.pdf168,63 kBAdobe PDF Accés restringit

Citació: Montalban, X. [et al.]. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. "Multiple sclerosis", Octubre 2009, vol. 15, núm. 10, p. 1195-1205.
Títol: A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis
Autor: Rovira, Àlex; Nos, Carlos; Montalbán, Xavier Veure Producció científica UPC; Sastre-Garriga, Jaume; Tintoré, Maria del Mar; Brieva, Luis; Aymerich Martínez, Francisco Javier Veure Producció científica UPC; Río, Jordi; Porcel, Joana; Borrás, Cecilia
Data: oct-2009
Tipus de document: Article
Resum: Inflammation and neurodegeneration may have differential impacts on disease evolution in the different forms of multiple sclerosis. However, a beneficial effect of immunomodulatory drugs should not be ruled out in primary progressive multiple sclerosis. Our aim is to investigate the safety and efficacy of interferon beta-1b in primary progressive multiple sclerosis. We conducted a double-blind, stratified, randomized, parallel group, phase II pilot study where patients with primary progressive multiple sclerosis or ‘transitional’ forms of multiple sclerosis received interferon beta-1b at doses of 8 MIU or placebo for 24 months. The main objective of the study was to investigate the safety and tolerability of interferon beta-1b. The primary efficacy variable was the time to neurological deterioration (Expanded Disability Status Scale) confirmed at 3 months. Seventy-three patients were included and three dropped out the study. More patients in the treatment arm had at least one related adverse event (94.4% versus 45.9%; p<0.001); no other significant differences in safety endpoints were observed. Time to neurological deterioration was not different between trial arms (log-rank test, p¼0.3135). Statistically significant differences favoring treatment were observed for the Multiple Sclerosis Functional Composite score at several timepoints, T1 and T2 lesion volume changes at 12 and 24 months, mean number of active lesions and proportion of patients with active lesions at 24 months. We conclude that interferon beta-1b is safe and well tolerated in patients with primary progressive multiple sclerosis and transitional multiple sclerosis. Positive effects of interferon beta on secondary clinical and magnetic resonance imaging outcomes were observed, but a beneficial effect on Expanded Disability Status Scale progression was not demonstrated.
ISSN: 1352-4585
URI: http://hdl.handle.net/2117/6185
DOI: 10.1177/1352458509106937
Apareix a les col·leccions:Departament d'Enginyeria de Sistemes, Automàtica i Informàtica Industrial. Articles de revista
Altres. Enviament des de DRAC
Comparteix:


Stats Mostra les estadístiques d'aquest ítem

SFX Query

Tots els drets reservats. Aquesta obra està protegida pels drets de propietat intel·lectual i industrial corresponents. Sense perjudici de les exempcions legals existents, queda prohibida la seva reproducció, distribució, comunicació pública o transformació sense l'autorització del titular dels drets.

Per a qualsevol ús que se'n vulgui fer no previst a la llei, dirigiu-vos a: sepi.bupc@upc.edu

 

Valid XHTML 1.0! Programari DSpace Copyright © 2002-2004 MIT and Hewlett-Packard Comentaris
Universitat Politècnica de Catalunya. Servei de Biblioteques, Publicacions i Arxius